Aplagon is Drug Discovery in Finland that focus on reperfusion injuries business. Founded in 2009. They cover business area such as developer, antithrombotic compound, complication, vascular intervention-relate blood vessel occlusion, biological mimetic, heparin proteoglycan, vascular injury-relate thrombotic occlusion, ischemic reperfusion injury, patient, unique and effective antithrombotic medicine, important safety advantage.
2009
( 15 years old in 2024 )
Reperfusion Injuries
-
Biomedicum Helsinki 2A
Tukholmankatu 8 A
00290 Helsinki
Finland
Private
developerantithrombotic compoundcomplicationvascular intervention-relate blood vessel occlusionbiological mimeticheparin proteoglycanvascular injury-relate thrombotic occlusionischemic reperfusion injurypatientunique and effective antithrombotic medicineimportant safety advantage
* We use standard office opening hours in near Aplagon's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Aplagon is Drug Discovery business from Finland that founded in 2009 (15 years old in 2024), Aplagon business is focusing on Reperfusion Injuries.
Aplagon headquarter office and corporate office address is located in Biomedicum Helsinki 2A Tukholmankatu 8 A 00290 Helsinki Finland.
Aplagon was founded in Finland.
In 2024, Aplagon is currently focus on reperfusion injuries sector.
Above is snippet of Google Trends for "reperfusion injuries" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Aplagon, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
